{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion&page=11",
    "query": {
      "intervention": "Infusion",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 13276,
    "total_pages": 1328,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T16:00:28.055Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05257408",
      "title": "Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Neoplasm",
        "Fallopian Tube Neoplasms",
        "Peritoneal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Relacorilant 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel 80 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel 100 mg/m^2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 381,
      "start_date": "2022-06-29",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Irvine, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05257408"
    },
    {
      "nct_id": "NCT02876055",
      "title": "Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Single shot interscalene nerve block",
          "type": "DRUG"
        },
        {
          "name": "Continuous interscalene nerve block",
          "type": "DRUG"
        },
        {
          "name": "Local Infiltration Analgesia (LIA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2016-11",
      "completion_date": "2018-02",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02876055"
    },
    {
      "nct_id": "NCT06171178",
      "title": "A Study of ASP1012 in Adults With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ASP1012",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-05-15",
      "completion_date": "2025-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06171178"
    },
    {
      "nct_id": "NCT02715843",
      "title": "Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Non-Hodgkin's B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "MT-3724",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Templates, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-10-11",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 3,
      "location_summary": "Tucson, Arizona • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02715843"
    },
    {
      "nct_id": "NCT00074750",
      "title": "Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "DTGM",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2003-12",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-22",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074750"
    },
    {
      "nct_id": "NCT03209349",
      "title": "Investigation of Cecal Intubation Rates and Pain Levels Between Water Exchange and Air Insufflation Flexible Sigmoidoscopy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Water Exchange Sigmoidoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Air Insufflation Sigmoidoscopy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Kelowna Gastroenterology Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "50 Years to 74 Years"
      },
      "enrollment_count": 90,
      "start_date": "2017-06-14",
      "completion_date": "2022-11-03",
      "has_results": false,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 1,
      "location_summary": "North Hills, California",
      "locations": [
        {
          "city": "North Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03209349"
    },
    {
      "nct_id": "NCT02519348",
      "title": "A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 433,
      "start_date": "2015-10-19",
      "completion_date": "2026-12-18",
      "has_results": true,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02519348"
    },
    {
      "nct_id": "NCT00407550",
      "title": "Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine HCL",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 19,
      "start_date": "2006-11",
      "completion_date": "2010-05-12",
      "has_results": true,
      "last_update_posted_date": "2019-05-02",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407550"
    },
    {
      "nct_id": "NCT02757391",
      "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Adenocarcinoma",
        "Metastatic Cholangiocarcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Digestive System Carcinoma",
        "Metastatic Esophageal Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IV Esophageal Cancer AJCC v7",
        "Stage IV Gastric Cancer AJCC v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Adoptive Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2019-08-09",
      "completion_date": "2020-10-02",
      "has_results": false,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02757391"
    },
    {
      "nct_id": "NCT04030091",
      "title": "Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "3 hours humulin R 100 IU/mL PIT",
          "type": "DRUG"
        },
        {
          "name": "2 hours humulin R 100 IU/mL PIT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sciema UG",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-09-06",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-04-01",
      "last_synced_at": "2026-10-30T16:00:28.055Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04030091"
    }
  ]
}